DRD Biotech

We creating rapid diagnostics in Russia

Development and manufacturing of diagnostic devices for laboratories and point-of-care

About us

Affordable rapid diagnostics for healthcare

DRD is engaged in the development and implementation of diagnostic devices - rapid blood tests based on innovative bio- and IT-technologies. The company was founded in 2014 in the Republic of Buryatia.

Contact us

Products

Laboratory and rapid diagnostic tests

NR2 antibodies

Biomarker of cerebral ischemia.
A high blood concentration of antibodies to NR2 (above the threshold of 2.0 ng / ml) correlates with an increased risk of ischemic stroke. The results of several studies have shown that an increase in the level of antibodies to NR2 above thresholds is a predictor of the development of transient ischemic attacks and / or ischemic stroke.

Product website

Rapid test for the brain damage

We are developing rapid tests for the diagnosis of Ischemic Stroke and Traumatic Brain Injury based on key biomarkers of brain damage.

More details